601607 上海醫藥
按盤價 
17.200 +0.150 (+0.880%) | 2025/12 - 人民幣(K¥) | 變動 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 283,579,601 | 3.03% | 260,295,089 | 231,981,300 | 215,824,259 | 191,909,156 | |
| 減：營業總成本 | 276,283,477 | 3.22% | 253,008,864 | 224,907,251 | 209,641,475 | 185,559,849 | |
| 其中:營業成本 | 253,163,121 | 3.49% | 228,966,947 | 201,494,923 | 187,281,149 | 165,180,104 | |
| 財務費用 | 1,407,224 | -4.98% | 1,485,758 | 1,313,192 | 1,245,369 | 1,239,584 | |
| 資產減值損失 | (1,018,556) | 65.79% | (561,277) | (331,471) | (140,441) | (898,616) | |
| 公允價值變動收益 | 332,121 | 62.92% | 404,731 | 218,738 | (206,004) | 116,798 | |
| 投資收益 | 3,170,144 | 733.31% | (68,123) | 533,117 | 1,811,394 | 976,195 | |
| 其中：對聯營企業和合營企業的投資收益 | 284,473 | -45.49% | 129,329 | 526,743 | 789,596 | 1,009,547 | |
| 營業利潤 | 9,942,086 | 22.13% | 7,667,235 | 9,014,650 | 8,205,486 | 7,184,388 | |
| 利潤總額 | 9,819,805 | 22.44% | 7,054,297 | 8,808,353 | 8,143,815 | 7,175,483 | |
| 減：所得稅費用 | 2,846,087 | 32.38% | 1,887,726 | 1,816,339 | 1,869,245 | 1,570,219 | |
| 淨利潤 | 6,973,718 | 18.80% | 5,166,570 | 6,992,015 | 6,274,569 | 5,605,264 | |
| 減：非控股權益 | 1,249,160 | -5.19% | 1,398,571 | 1,374,863 | 1,181,102 | 1,109,047 | |
| 股東淨利潤 | 5,724,558 | 25.74% | 3,768,000 | 5,617,152 | 5,093,467 | 4,496,217 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 1.540 | 25.20% | 1.020 | 1.610 | 1.790 | 1.580 | |
| 每股派息 (元) * | 0.470 | 27.03% | 0.410 | 0.610 | 0.420 | 0.480 | |
| 每股淨資產 (元) * | 20.465 | 5.87% | 18.500 | 18.137 | 17.367 | 15.958 | |
| 審計意見 # | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 01/04/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
